These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25224470)

  • 21. Cancer detection using whole-genome sequencing of cell free DNA.
    Leary RJ; Sausen M; Diaz LA; Velculescu VE
    Oncotarget; 2013 Aug; 4(8):1119-20. PubMed ID: 23912395
    [No Abstract]   [Full Text] [Related]  

  • 22. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutagen hypersensitivity as a biomarker of genetic predisposition to carcinogenesis.
    Olden K
    J Natl Cancer Inst; 1994 Nov; 86(22):1660-1. PubMed ID: 7966386
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?
    Parker JS; Perou CM
    Cancer Cell; 2015 Aug; 28(2):149-50. PubMed ID: 26267531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour heterogeneity and clonality--an old theme revisited.
    Fey MF; Tobler A
    Ann Oncol; 1996 Feb; 7(2):121-8. PubMed ID: 8777166
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
    Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multigene Panel Testing in Oncology Practice: How Should We Respond?
    Kurian AW; Ford JM
    JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167
    [No Abstract]   [Full Text] [Related]  

  • 28. Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics.
    Kumar M; Choudhury Y; Ghosh SK; Mondal R
    Tumour Biol; 2018 Feb; 40(2):1010428318760342. PubMed ID: 29484962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The bewildering complexity of cancer].
    Jordan B
    Med Sci (Paris); 2011; 27(8-9):781-6. PubMed ID: 21880268
    [No Abstract]   [Full Text] [Related]  

  • 30. Is there a role for intraoperative flow cytometry in brain tumor surgery?
    Vartholomatos G; Alexiou GA; Gerogianni P; Lykoudis E; Voulgaris S; Kyritsis AP
    Cytometry B Clin Cytom; 2015; 88(5):289-90. PubMed ID: 25728803
    [No Abstract]   [Full Text] [Related]  

  • 31. Advances in Circulating Tumor DNA Analysis.
    Perakis S; Auer M; Belic J; Heitzer E
    Adv Clin Chem; 2017; 80():73-153. PubMed ID: 28431643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid Biopsy Holds Its Own in Tumor Profiling.
    Cancer Discov; 2016 Jul; 6(7):686. PubMed ID: 27287288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Implications of "Random Chance" in Cancer Genesis: Why Stochastic Can Be a Dirty Word.
    Meisenberg BR
    JAMA Oncol; 2015 Aug; 1(5):575-6. PubMed ID: 26181509
    [No Abstract]   [Full Text] [Related]  

  • 34. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.
    Saliou A; Bidard FC; Lantz O; Stern MH; Vincent-Salomon A; Proudhon C; Pierga JY
    Expert Rev Mol Diagn; 2016; 16(1):39-50. PubMed ID: 26568208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemistry 2015: Protein correlates of molecular alterations and predictive testing.
    Hornick JL
    Semin Diagn Pathol; 2015 Sep; 32(5):323-4. PubMed ID: 26250936
    [No Abstract]   [Full Text] [Related]  

  • 36. Circulating DNA biomarkers: a primer for metastatic colorectal cancer?
    Eng C
    Lancet Oncol; 2015 Aug; 16(8):878-9. PubMed ID: 26184521
    [No Abstract]   [Full Text] [Related]  

  • 37. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 38. Whole Exome Profiling of Ocular Surface Squamous Neoplasia.
    Galor A; Karp CL; Sant D; Joag M; Shalabi N; Gustafson CB; Wang G
    Ophthalmology; 2016 Jan; 123(1):216-217.e1. PubMed ID: 26271840
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review.
    Hemminki K; Xu G; Le Curieux F
    J Natl Cancer Inst; 2000 Sep; 92(18):1536-7. PubMed ID: 10995815
    [No Abstract]   [Full Text] [Related]  

  • 40. Specific gene patterns and molecular pathways related to human carcinogenesis in different populations among various geographic locations.
    Al Moustafa AE; Al-Antary NT
    Cancer; 2016 Apr; 122(7):1134-5. PubMed ID: 26849403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.